NEW YORK (GenomeWeb) – Epic Sciences said today that it has completed a $40 million Series D financing.
Hermed Capital led the round, which also included Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabby Capital, and VI Ventures.
Epic said it plans to use the funds to accelerate clinical validation of its pipeline of oncology tests, which is led by the firm's AR-v7 prostate cancer assay, now being commercialized in partnership with Genomic Health as OncotypeDx AR-V7 Nucleus Detect.
The money will also help Epic work to enhance its proprietary "No Cell Left Behind" technology to include characterization of rare leukocyte cell populations using digital imaging and big data analytics, the firm said. The company hopes this will allow the platform to glean insights into the cellular drivers of response or resistance to new therapeutics like cancer immunotherapies.